Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
A Russian drone strike targeted a bus carrying coal miners in central Ukraine, killing at least a dozen workers hours after Kyiv announced a postponement of diplomatic negotiations. The attack, condemned as a deliberate strike on civilians, marks one of the deadliest single incidents for Ukraine's energy sector since the invasion began.
A Russian drone strike targeted a bus carrying coal miners in Ukraine's Dnipropetrovsk region on Sunday, killing at least 12 workers and wounding eight others, in what Ukrainian officials describe as a deliberate attack on civilian infrastructure.
Elon Musk has issued a forceful rebuttal to allegations linking him to the late financier and convicted sex offender Jeffrey Epstein, following the release of emails showing past correspondence. The tech mogul asserts he is being unfairly targeted and positions himself as a champion for Epstein's victims.
As Visa prepares to report its first-quarter results, investors are weighing its dividend strategy against earnings expectations. We break down the capital required to generate targeted monthly income from its payouts and what moving parts could affect the yield.
Oshkosh Corporation topped revenue expectations in its latest quarter, but profit fell short as tariffs and cost pressures squeezed margins. The specialty vehicle maker's 2026 outlook balances targeted growth in some segments against persistent challenges in construction markets.
Shares in Alligator Energy (ASX:AGE) jumped sharply after the company announced key progress at its Samphire uranium project in South Australia, including the launch of a field recovery trial and advancing mining lease approvals, setting the stage for a bankable feasibility study targeted for early 2027.
The FDA clearance of Spectrum Dynamics' Veritas.AI platform marks a significant step forward for nuclear imaging, promising to cut scan times in half and enhance image clarity for critical applications like cancer theranostics.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.
PennyMac Mortgage Investment Trust (PMT) reported a robust fourth quarter, highlighted by a 13% return on equity and strategic advancements in its securitization business. Executives outlined a confident outlook for 2026, emphasizing disciplined risk management and growth in targeted lending segments.
GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.
Nurix Therapeutics, a clinical-stage biopharma company, is gaining attention for its novel protein degradation platform. With strong early data for its lead drug, key regulatory designations, and strategic partnerships with industry giants, the company is positioning itself to address unmet needs in multi-billion dollar oncology markets.
New late-breaking data for Nektar Therapeutics' lead drug candidate, rezpegaldesleukin, suggests systemic anti-inflammatory benefits in patients with comorbid asthma, potentially expanding its market reach and strengthening the investment case for the biopharma firm.
A sophisticated, high-conviction options trade by a large investor signals strong confidence in Edwards Lifesciences' fundamentals, with a potential breakout eyed for early 2026 tied to regulatory milestones and sustained growth in its mitral valve business.
Specialist asset manager Cohen & Steers (NYSE: CNS) is attracting bullish attention as its focus on real assets aligns with a shifting monetary policy landscape. After a prolonged period of outflows, the firm is seeing renewed investor interest.
Facing persistently weak natural gas prices, APA Corporation announces significant production cuts across its U.S. operations while reaffirming its commitment to a multi-billion dollar share repurchase program, signaling a strategic pivot towards capital discipline over volume growth.
